Table 3.
Total count of lipid vacuoles representing microvesicular or macrovesicular steatosis determined using QuHAnT for ~50 images per slide of TCDD-treated mouse liver sections.
| Vacuolization type ([count/tissue area] × 10−6) | ||
|---|---|---|
| Dose (µg/kg TCDD) | Microvesicular (≤176 µm2)a |
Macrovesicular (≥176 µm2)a |
| 0 | 28.70 ± 8.55 | 1.42 ± 0.28 |
| 0.001 | 12.40 ± 3.32 | 0.62 ± 0.08 |
| 0.01 | 19.00 ± 11.2 | 0.76 ± 0.23 |
| 0.03 | 70.30 ± 38.6 | 1.14 ± 0.36 |
| 0.1 | 22.10 ± 12.2 | 1.09 ± 0.35 |
| 0.3 | 28.20 ± 12.8 | 1.03 ± 0.20 |
| 1 | 100.08 ± 71.5829 | 3.42 ± 2.61 |
| 3 | 117.26 ± 41.3956 | 6.47 ± 2.43 |
| 10 | 437.40b ± 71.298 | 97.30b ± 35.10 |
| 30 | 555.13b ± 65.1883 | 251.47b ± 56.02 |
Note. ANOVA = analysis of variance; QuHAnT = quantitative histological analysis tool; TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin.
a
Area of 176 µm2 was estimated based on a diameter of 15 µm previously reported to distinguish between microvesicular steatosis from macrovesicular steatosis (Zaitoun et al. 2001).
b
Significant differences (p ≤ .05) compared to vehicle control determined by ANOVA followed by Dunnett’s post hoc test.